CAR T-Cell Therapy Market Size to Reach USD 30,777.6 Million in 2032
The CAR T-Cell Therapy Market size was USD 4,557.5 Million in 2024 and is expected to register a revenue CAGR of 26.9% during the forecast period
09 April, 2025 – Increase in prevalence of cancer is a key driver driving CAR T-Cell Therapy market revenue growth. According to the American Cancer Society, Chronic lymphocytic leukemia (CLL) in the United States in 2025 are approximately 23,690 new cases of CLL (14,340 in men and 9,350 in women), approximately 4,460 deaths from CLL (2,810 men and 1,650 females). CLL accounts for almost one in every three new instances of leukemia in the United States, as well as approximately 1% of all malignancies. CLL primarily affects older persons. The typical age at diagnosis is roughly 70 years. Although men are significantly more likely to get CLL than women, both sexes have an average lifetime risk of approximately ½ of 1%.
On January 2025, CARsgen Therapeutics Holdings Limited, a company specializing in innovative CAR T-cell therapies for hematologic malignancies and solid tumors, has announced agreements with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise. Together, they will co-invest in UCARsgen Biotech Limited, a China-based biotechnology firm dedicated to developing allogeneic CAR-T cell therapies for hematologic malignancies.
An further significant issue is the long “vein-to-vein” interval between leukapheresis and CAR-T delivery. This process can take several weeks, and by the time the CAR-T cells are produced, patients may be disqualified due to disease progression or deterioration in organ function. Because production is often limited to a few locations, cells must be collected and delivered to specific manufacturing facilities for T-cell engineering. There is a dearth of standardized protocols for apheresis collection. 19 Sponsors of CAR T-cell therapy (pharmaceutical companies and clinical trials) typically have their own methods for cell collection, labeling, and transportation. Increased demand and a lack of standard collection techniques put undue strain on apheresis units, compromising the quality of the product collected.
Key Highlights:
- BCMA segment is expected to register the fastest market share over the forecast period. Chimeric antigen receptor (CAR) T-cell therapy is a significant advance in the treatment of hematologic malignancies, particularly relapsed or refractory multiple myeloma (MM). BCMA is predominantly expressed in mature B lymphocytes and Multiple Myeloma (MM) cells. BCMA is an extremely appealing target antigen for immunotherapy due to its limited expression in non-malignant tissue but practically universal expression on MM cells.
- Leukemia segment is expected to account for the largest growth rate over the forecast period. According to the National Cancer Institute, in 2024, it is expected that 20,800 new instances of acute myeloid leukemia would be diagnosed, with 11,220 people dying from the disease. Acute myeloid leukemia is more common in older persons and among males than in women. New cases of acute myeloid leukemia occurred at an incidence of 4.2 per 100,000 men and women annually. The death rate was 2.7 per 100,000 men and women per year.
- North America accounted for the largest market revenue share in the CAR T-cell therapy market in 2024 due to the increase in prevalence of cancer and technological advancements of CAR T-cell therapies. On November 2024, Vyriad, Inc., a clinical-stage biotechnology firm creating next-generation targeted genetic medicines, has established a strategic partnership with Novartis to find and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. The agreement will combine Vyriad’s active targeting lentiviral vector platform with Novartis’ knowledge and competence in cell therapy innovation. Novartis and Vyriad will collaborate to identify and develop in vivo CAR-T cell treatment candidates, which Novartis will push to clinical trials. Vyriad will receive an up-front payment, milestone payments, and tiered royalties for each program.
- Some major companies in the market report include Bristol-Myers Squibb, Immatics, GSK, Pfizer, OncoTherapy Science, Johnson & Johnson, BioNTech, Gilead Sciences, Merck & Co., Inc., Allogene Therapeutics, Anixa Biosciences, Autolus Therapeutics, Cartesian Therapeutics Inc, Novartis AG, CARsgen Therapeutics Holdings Limited, and Others.
- On April 2024, Bristol Myers Squibb and 2seventy bio, Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple myeloma who have undergone at least two previous treatments, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. The approval is based on findings from the KarMMa-3 trial.
- On January 2024, AbbVie and Umoja Biopharma, an early clinical-stage biotechnology company, have announced two exclusive option and licensing agreements to develop numerous in-situ produced CAR-T cell treatment candidates in oncology on Umoja’s patented VivoVec platform. The first deal gives AbbVie the exclusive right to license Umoja’s CD19-directed in-situ produced CAR-T cell therapy prospects. This includes Umoja’s flagship clinical program for hematologic malignancies, UB-VV111, which is now in the IND-enabling phase. Under the terms of the second agreement, AbbVie and Umoja will collaborate to develop up to four additional in-situ produced CAR-T cell therapy candidates for AbbVie-selected discovery targets.
Unlock the key to transforming your business strategy with our CAR T-Cell Therapy market insights
Navistrat Analytics has segmented CAR T-Cell Therapy market based on type, antigen type, therapy type, application, and end-use:
- Type Outlook (Revenue, USD Million; 2022-2032)
- Kymriah
- Yescarta
- Tecartus
- Abecma
- Carvykti
- Others
- Antigen Type Outlook (Revenue, USD Million; 2022-2032)
- CD19
- BCMA
- CD22
- CD20
- Others
- Therapy Type Outlook (Revenue, USD Million; 2022-2032)
- Autologous CAR T-cell Therapy
- Allogeneic CAR T-cell Therapy
- Indication Outlook (Revenue, USD Million; 2022-2032)
- Leukemia
- Lymphoma
- Multiple Myleoma
- Autoimmune Disorders
- Others
- End-Use Outlook (Revenue, USD Million; 2022-2032)
- Hospitals & Cancer Treatment Centers
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Regional Outlook (Revenue, USD Billion; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America